Humedix Co Ltd (200670) - Total Assets
Based on the latest financial reports, Humedix Co Ltd (200670) holds total assets worth ₩288.63 Billion KRW (≈ $195.60 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See net assets of Humedix Co Ltd for net asset value and shareholders' equity analysis.
Humedix Co Ltd - Total Assets Trend (2015–2024)
This chart illustrates how Humedix Co Ltd's total assets have evolved over time, based on quarterly financial data.
Humedix Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Humedix Co Ltd's total assets of ₩288.63 Billion consist of 64.1% current assets and 35.9% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩78.82 Billion | 44.2% |
| Accounts Receivable | ₩20.48 Billion | 8.2% |
| Inventory | ₩26.39 Billion | 10.6% |
| Property, Plant & Equipment | ₩51.81 Billion | 20.8% |
| Intangible Assets | ₩2.37 Billion | 1.0% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2015–2024)
This chart illustrates how Humedix Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 200670 market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Humedix Co Ltd's current assets represent 64.1% of total assets in 2024, a decrease from 71.1% in 2015.
- Cash Position: Cash and equivalents constituted 44.2% of total assets in 2024, down from 58.4% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2015.
- Asset Diversification: The largest asset category is cash and equivalents at 44.2% of total assets.
Humedix Co Ltd Competitors by Total Assets
Key competitors of Humedix Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC
|
USA | $5.76 Million |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥31.46 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867
|
China | CN¥8.15 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
|
Guobang Pharma Ltd
SHG:605507
|
China | CN¥10.58 Billion |
Humedix Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.22 | 8.42 | 2.38 |
| Quick Ratio | 7.93 | 6.69 | 1.86 |
| Cash Ratio | 0.00 | 5.45 | 0.00 |
| Working Capital | ₩163.13 Billion | ₩130.48 Billion | ₩50.58 Billion |
Humedix Co Ltd - Advanced Valuation Insights
This section examines the relationship between Humedix Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.63 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 13.5% |
| Total Assets | ₩249.75 Billion |
| Market Capitalization | $246.43 Million USD |
Valuation Analysis
Below Book Valuation: The market values Humedix Co Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Humedix Co Ltd's assets grew by 13.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Humedix Co Ltd (2015–2024)
The table below shows the annual total assets of Humedix Co Ltd from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩249.75 Billion ≈ $169.25 Million |
+13.54% |
| 2023-12-31 | ₩219.98 Billion ≈ $149.08 Million |
-3.15% |
| 2022-12-31 | ₩227.14 Billion ≈ $153.93 Million |
+5.22% |
| 2021-12-31 | ₩215.86 Billion ≈ $146.29 Million |
+22.90% |
| 2020-12-31 | ₩175.65 Billion ≈ $119.03 Million |
+26.89% |
| 2019-12-31 | ₩138.42 Billion ≈ $93.81 Million |
+7.91% |
| 2018-12-31 | ₩128.28 Billion ≈ $86.93 Million |
-1.13% |
| 2017-12-31 | ₩129.74 Billion ≈ $87.92 Million |
-1.08% |
| 2016-12-31 | ₩131.16 Billion ≈ $88.88 Million |
+13.17% |
| 2015-12-31 | ₩115.90 Billion ≈ $78.54 Million |
-- |
About Humedix Co Ltd
Humedix Co., Ltd. engages in the manufacture and sale of various pharmaceutical products in South Korea. The company offers prescription medicines, active pharmaceutical ingredients, medical devices, cosmetics, and health functional food products. It is also involved in the manufacture and distribution of anticancer drugs. The company was formerly known as HVLS Co., Ltd. and changed its name to H… Read more